What's Happening?
Caristo Diagnostics is set to present new findings at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting, highlighting its AI-powered technologies for coronary inflammation and plaque analysis. The presentations will include
three abstracts nominated for the SCCT Young Investigator Award, showcasing the use of Caristo's FAI-Score technology on non-contrast cardiac CT. These findings are part of the University of Oxford-led ORFAN registry, which supports the use of AI in cardiovascular risk stratification.
Why It's Important?
The advancements presented by Caristo Diagnostics underscore the growing role of AI in cardiovascular disease management. By enhancing risk stratification and early detection of coronary inflammation, these technologies have the potential to improve patient outcomes and reduce the incidence of heart attacks. The integration of AI in medical imaging represents a significant shift towards more precise and personalized healthcare, which could lead to better resource allocation and treatment strategies in cardiology.
What's Next?
Caristo Diagnostics will continue to develop its AI technologies and expand its global registry to include long-term clinical data from up to 250,000 patients. The company aims to further validate its technologies and explore new applications in cardiovascular care. As AI becomes increasingly integrated into medical practice, Caristo's innovations could set new standards for diagnosing and managing heart disease.
